驱动压限制策略对ARDS患者结局的影响:随机对照试验的荟萃分析
该荟萃分析纳入4项随机对照试验共431例ARDS患者,比较在肺保护性通气基础上实施驱动压限制策略(干预组)与单纯肺保护性通气(对照组)的效果。干预策略包括降低潮气量和/或滴定呼气末正压。结果显示两组随机化后第1、2、3天驱动压均值差分别为-2.17、-2.09、-2.15 cmH2O,均无统计学显著差异;死亡率35.7% vs 39.0%(RR 0.63, 95%CI 0.20-1.94, p=0.28)及无呼吸机天数(p=0.88)无显著差异;干预组ICU住院时间缩短(均数差-2.40天,95%CI -3.31至-1.49, p=0.004)。作者认为在已应用肺保护性通气时进一步限制驱动压可能难以实现,这或可解释其对死亡率和无呼吸机天数等结局的中性效应。
要点
- 在已实施肺保护性通气的ARDS患者中,加用驱动压限制策略(降低潮气量和/或滴定PEEP)后第1、2、3天驱动压较对照组分别仅降低2.17、2.09、2.15 cmH2O,均未达统计学显著。
- 驱动压限制策略组死亡率35.7% vs 对照组39.0%,RR 0.63(95%CI 0.20-1.94, p=0.28),无统计学显著差异。
- 无呼吸机天数两组无统计学显著差异(p=0.88)。
- 驱动压限制策略组ICU住院时间较对照组缩短2.40天(均数差-2.40天,95%CI -3.31至-1.49, p=0.004)。
- 作者认为,在肺保护性通气已应用时进一步限制驱动压可能难以实现,这可能解释其对死亡率和无呼吸机天数的中性效应。
适用人群与场景
- 急性呼吸窘迫综合征(ARDS)患者,已接受肺保护性通气。
处置流程与药物剂量
- 干预组在肺保护性通气基础上实施驱动压限制策略,包括降低潮气量和/或滴定呼气末正压(PEEP),具体方案各试验间存在异质性。
研究设计与关键结果
- 研究类型:随机对照试验的荟萃分析,纳入4项试验,共431例ARDS患者。
- 干预与对照:干预组为肺保护性通气基础上实施驱动压限制策略(降低潮气量和/或滴定PEEP),对照组为单纯肺保护性通气。
- 主要终点:随机化后第1、2、3天驱动压均数差分别为-2.17、-2.09、-2.15 cmH2O,均无统计学显著差异。
- 死亡率:干预组35.7% vs 对照组39.0%,RR 0.63(95%CI 0.20-1.94, p=0.28),无统计学显著差异。
- 无呼吸机天数:两组无统计学显著差异(p=0.88)。
- ICU住院时间:干预组较对照组缩短2.40天(均数差-2.40天,95%CI -3.31至-1.49, p=0.004)。
证据类型、等级与局限
- 证据类型:随机对照试验的荟萃分析(PROSPERO注册号CRD420251141653)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在已应用肺保护性通气时,进一步限制驱动压可能难以实现,这或可解释驱动压限制策略对死亡率和无呼吸机天数的中性效应。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Lower driving pressure is associated with better outcomes in patients with acute respiratory distress syndrome (ARDS) based on observational studies. However, individual randomized controlled trials provided inconclusive evidence. We synthesized evidence from randomized controlled trials to examine whether implementation of driving pressure-limiting strategies is feasible and improves outcomes.
METHODS: This meta-analysis was registered with PROSPERO (CRD420251141653). PubMed, Scopus, CENTRAL and references were searched for trials comparing driving pressure-limiting strategies on top of lung protective ventilation ("intervention" group) versus lung protective ventilation alone ("control" group) in ARDS. Outcomes were feasibility of intervention, all-cause mortality, ventilator-free days and length of intensive care unit (ICU) stay.
RESULTS: Four trials, enrolling 431 patients and implementing heterogenous driving pressure-limiting strategies (namely, tidal volume reduction and/or positive end-expiratory pressure titration), were included. There were no statistically significant mean differences in post-randomization driving pressure (namely, - 2.17, - 2.09 and - 2.15 cmH2O on study day 1, 2 and 3, respectively) between groups. There was no statistically significant difference between "intervention" versus "control" group in terms of mortality [35.7% versus 39.0%; relative risk 0.63, 95% confidence interval (CI) 0.20 to 1.94, p = 0.28] or ventilator-free days (p = 0.88). Driving pressure-limiting strategies were associated with shorter length of ICU stay (mean difference - 2.40 days, 95% CI - 3.31 to - 1.49, p = 0.004).
CONCLUSIONS: When lung protective ventilation is already applied, further limitation of driving pressure may be hard to achieve. This inability to meaningfully limit driving pressure might explain the neutral effect of driving pressure-limiting strategies on outcomes, such as mortality and ventilator-free days.
参考来源
- Agrafiotis M, Georgopoulos M, Akoumianaki E, et al. Effect of driving pressure-limiting strategies on outcomes of patients with ARDS: a meta-analysis of randomized controlled trials. Crit Care. 2026. PMID: 41787551. doi:10.1186/s13054-026-05876-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。